BR112018007159A2 - formulações de análogos de pthrp, emplastros transdérmicos dos mesmos e usos dos mesmos - Google Patents

formulações de análogos de pthrp, emplastros transdérmicos dos mesmos e usos dos mesmos

Info

Publication number
BR112018007159A2
BR112018007159A2 BR112018007159A BR112018007159A BR112018007159A2 BR 112018007159 A2 BR112018007159 A2 BR 112018007159A2 BR 112018007159 A BR112018007159 A BR 112018007159A BR 112018007159 A BR112018007159 A BR 112018007159A BR 112018007159 A2 BR112018007159 A2 BR 112018007159A2
Authority
BR
Brazil
Prior art keywords
formulations
bone
transdermal patches
pthrp
pthrp analog
Prior art date
Application number
BR112018007159A
Other languages
English (en)
Inventor
Harris Alan
Hamed Ehab
Hattersley Gary
Saeh Jamal
Original Assignee
3M Innovative Properties Co
Radius Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co, Radius Health Inc filed Critical 3M Innovative Properties Co
Publication of BR112018007159A2 publication Critical patent/BR112018007159A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a formulações análogas pthrp para a administração transdérmica de uma quantidade terapeuticamente eficaz de um análogo pthrp bem como emplastros transdérmicos preparados usando estas formulações, métodos para preparar as formulações de acordo com a invenção e emplastros e métodos para usar estas formulações e emplastros para tratar osteoporose, osteopenia, osteoartrite e/ou fratura óssea , melhorar a densidade mineral óssea (dmo), para melhorar a pontuação do osso trabecular (tbs) e tratar, prevenir e/ou reduzir fraturas ósseas.
BR112018007159A 2015-10-09 2016-10-08 formulações de análogos de pthrp, emplastros transdérmicos dos mesmos e usos dos mesmos BR112018007159A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239773P 2015-10-09 2015-10-09
US201562239774P 2015-10-09 2015-10-09
US201562239801P 2015-10-09 2015-10-09
US201662324336P 2016-04-18 2016-04-18
US201662353249P 2016-06-22 2016-06-22
US201662396196P 2016-09-18 2016-09-18
PCT/US2016/056196 WO2017062922A1 (en) 2015-10-09 2016-10-08 Formulations of pthrp analogues, transdermal patches thereof, and uses thereof

Publications (1)

Publication Number Publication Date
BR112018007159A2 true BR112018007159A2 (pt) 2018-11-06

Family

ID=58488710

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018007159A BR112018007159A2 (pt) 2015-10-09 2016-10-08 formulações de análogos de pthrp, emplastros transdérmicos dos mesmos e usos dos mesmos

Country Status (22)

Country Link
US (1) US20190091138A1 (pt)
EP (2) EP3909566A1 (pt)
JP (3) JP6867379B2 (pt)
KR (1) KR20180067573A (pt)
CN (2) CN108697881A (pt)
AU (2) AU2016334378B2 (pt)
BR (1) BR112018007159A2 (pt)
CA (1) CA3000533C (pt)
CY (1) CY1124657T1 (pt)
DK (1) DK3359241T3 (pt)
ES (1) ES2881461T3 (pt)
HR (1) HRP20211127T1 (pt)
HU (1) HUE055658T2 (pt)
IL (2) IL287604B2 (pt)
LT (1) LT3359241T (pt)
MX (1) MX2018004192A (pt)
PL (1) PL3359241T3 (pt)
PT (1) PT3359241T (pt)
RS (1) RS62394B1 (pt)
SG (1) SG11201802871UA (pt)
SI (1) SI3359241T1 (pt)
WO (1) WO2017062922A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927067T3 (es) * 2015-03-03 2022-11-02 Radius Health Inc Abaloparatida combinada con alendronato para la reducción de las fracturas óseas no vertebrales
WO2017184355A1 (en) 2016-04-18 2017-10-26 Radius Health, Inc. Formulations of abaloparatide, transdermal patches thereof, and uses thereof
US10996208B2 (en) 2017-04-28 2021-05-04 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
CA3167644A1 (en) * 2017-09-22 2019-03-28 Asahi Kasei Pharma Corporation Teriparatide-containing liquid pharmaceutical composition having excellent pharmacokinetics and/or safety
CN107674113A (zh) * 2017-10-20 2018-02-09 广东医科大学 一种小分子活性肽及其制备方法、及采用该活性肽的透皮贴剂的制备方法与其用途
CN110054679B (zh) * 2018-01-18 2021-05-04 成都圣诺生物制药有限公司 一种合成Abaloparatide的方法
CN109602911B (zh) * 2019-01-09 2020-11-10 厦门大学 硫酸钙晶须或其组合物在制备皮肤促渗剂中的用途
WO2020174443A1 (en) 2019-02-28 2020-09-03 Radius Health, Inc. Transdermal system for the delivery of abaloparatide and method of use
WO2021051082A1 (en) * 2019-09-12 2021-03-18 Radius Health, Inc. Methods of improving spinal fusion with abaloparatide
WO2021149012A1 (en) 2020-01-24 2021-07-29 Radius Health, Inc. Methods of stimulating bone growth with abalopartide and denosumab
US20220378881A1 (en) * 2021-05-25 2022-12-01 Radius Health, Inc. Treatment and prevention of osteoporosis in high body mass index individuals
WO2023281447A1 (en) 2021-07-07 2023-01-12 Radius Health, Inc. Methods of treating a cardiovascular ischemic event
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample
US11964121B2 (en) 2021-10-13 2024-04-23 Satio, Inc. Mono dose dermal patch for pharmaceutical delivery

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032698A1 (en) * 2003-07-14 2005-02-10 Nps Allelix Corp. Stabilized formulation of parathyroid hormone
WO2007106597A2 (en) * 2006-03-15 2007-09-20 Alza Corporation Method for the transdermal delivery of parathyroid hormone agents for treating osteopenia
BRPI0719821B8 (pt) * 2006-10-03 2021-05-25 Ipsen Pharma Sas composição estável na armazenagem apropriada para administração a pacientes
WO2009054988A1 (en) * 2007-10-23 2009-04-30 Alza Corporation Transdermal sustained release drug delivery
CN102448482A (zh) * 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
KR101728194B1 (ko) * 2010-02-24 2017-05-02 히사미쓰 세이야꾸 가부시키가이샤 마이크로 니들 디바이스 및 그 제조 방법
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
US20130006217A1 (en) * 2011-04-22 2013-01-03 Gary Hattersley METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES
CA2857502C (en) * 2011-11-30 2019-08-13 3M Innovative Properties Company Microneedle device including a peptide therapeutic agent and an amino acid and methods of making and using the same
CN102526220A (zh) * 2012-01-10 2012-07-04 上海市中医医院 一种治疗期前收缩的中药贴剂及其制备方法和应用
US9581438B2 (en) * 2012-12-31 2017-02-28 General Electric Company Systems and methods for control of a non-destructive testing system
CN114848614A (zh) * 2013-07-18 2022-08-05 曼金德公司 热稳定性干粉药物组合物和方法
US10905744B2 (en) * 2015-10-07 2021-02-02 Cyprumed Gmbh Pharmaceutical formulations for the oral delivery of peptide drugs

Also Published As

Publication number Publication date
JP6867379B2 (ja) 2021-04-28
SG11201802871UA (en) 2018-05-30
DK3359241T3 (da) 2021-07-19
CN115025068A (zh) 2022-09-09
JP7146011B2 (ja) 2022-10-03
CY1124657T1 (el) 2022-07-22
CA3000533C (en) 2023-10-17
HUE055658T2 (hu) 2021-12-28
JP2021119141A (ja) 2021-08-12
WO2017062922A1 (en) 2017-04-13
JP2018536631A (ja) 2018-12-13
IL258441B (en) 2021-12-01
IL258441A (en) 2018-05-31
IL287604B2 (en) 2024-04-01
HRP20211127T1 (hr) 2021-10-15
EP3359241A1 (en) 2018-08-15
AU2016334378A1 (en) 2018-04-19
AU2016334378B2 (en) 2021-12-02
EP3359241B1 (en) 2021-04-14
EP3359241A4 (en) 2019-06-26
EP3909566A1 (en) 2021-11-17
PT3359241T (pt) 2021-07-21
IL287604B1 (en) 2023-12-01
SI3359241T1 (sl) 2021-11-30
KR20180067573A (ko) 2018-06-20
CN108697881A (zh) 2018-10-23
CA3000533A1 (en) 2017-04-13
US20190091138A1 (en) 2019-03-28
JP2022174274A (ja) 2022-11-22
PL3359241T3 (pl) 2021-12-20
RS62394B1 (sr) 2021-10-29
ES2881461T3 (es) 2021-11-29
AU2021269361A1 (en) 2021-12-16
IL287604A (en) 2021-12-01
LT3359241T (lt) 2021-10-11
MX2018004192A (es) 2018-09-26

Similar Documents

Publication Publication Date Title
BR112018007159A2 (pt) formulações de análogos de pthrp, emplastros transdérmicos dos mesmos e usos dos mesmos
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112018071585A2 (pt) formulações de um inibidor de lsd1
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112016026809A2 (pt) compostos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol substituído como agentes de alvejamento de asgpr
BR112017023904A2 (pt) derivados indol mono- ou dissubstituídos como inibidores da replicação viral da dengue
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112012004696A2 (pt) compostos e composições como moduladores da atividade de tlr
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
BR112019001253A2 (pt) composto, composição farmacêutica, e, métodos de tratamento de câncer ou de atrofia muscular e de doença de parkinson.
BR112017015123A2 (pt) derivados de indol como inibidores da replicação viral do dengue
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
BR112017008039A2 (pt) derivados de pirazol como inibidores de nik
BR112017007715A2 (pt) derivados de tienopirimidina como inibidores de nik
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
BR112018011607A2 (pt) composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico.
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
DK3168214T3 (da) Substituerede 2-thioxo-imidazolidin-4-oner og spiro- analoger deraf, aktiv anti-canceringrediens, farmaceutisk sammensætning, medicinpræparat, fremgangsmåde til behandling af prostatacancer
BR112015010196A2 (pt) métodos de tratar doença do fígado
BR112016030728A2 (pt) método para tratar ou prevenir uma inflamação induzida por bactérias em um indivíduo, composição imunogênica, composição farmacêutica, uso da composição imunogênica, método para produzir uma composição imunogênica, e, método para tratar ou prevenir uma doença
BR112022001002A2 (pt) Solvato de dmf, forma a, forma c, processos para a preparação do solvato de dmf, para a preparação da forma a de relugolix anidra, para a preparação da forma b de relugolix anidra e para a preparação da forma c de relugolix anidra, composição farmacêutica, e, método de tratamento de doença
BR112017015597A2 (pt) moduladores dos receptores da adenosina a3

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: RADIUS HEALTH, INC. (US) ; KINDEVA DRUG DELIVERY L.P. (US)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: RADIUS HEALTH, INC. (US) ; 3M INNOVATIVE PROPERTIES COMPANY (US)

Free format text: ANULADA A PUBLICACAO CODIGO 25.1 NA RPI NO 2660 DE 28/12/2021 POR TER SIDO INDEVIDA.

B25G Requested change of headquarter approved

Owner name: RADIUS HEALTH, INC. (US) ; 3M INNOVATIVE PROPERTIES COMPANY (US)

B25A Requested transfer of rights approved

Owner name: RADIUS HEALTH, INC. (US) ; KINDEVA DRUG DELIVERY L.P. (US)